On October 4, Alnylam Pharmaceuticals discontinued development of revusiran, its RNA interference (RNAi) therapeutic for treating transthyretin amyloidosis with cardiomyopathy, one of the two main ...

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced the discontinuation of the development of its late stage pipeline drug, Revusiran due to safety concerns. Goldman Sachs’ Terence Flynn ...

Alnylam shocked the Street by announcing the termination of its Phase III drug candidate revusiran. Management was foggy on the details, but it sounds as though higher mortality and insufficient ...

October was a bad month for Alnylam. Its shares plunged almost 50 percent after it abruptly scrapped its Phase 3 candidate revusiran, citing a disproportionate number of deaths in the active arm ...

Alnylam Pharmaceuticals (NASDAQ: ALNY) announced on Oct. 5 that it was discontinuing development of revusiran in treating hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM). The drug had ...

Alnylam Pharmaceuticals is halting development of revusiran following a Phase III trial of the RNA interference (RNAi) candidate in which 18 patients died. The company said in a statement it was ...

Shares in Alnylam went into freefall yesterday after the US biotech revealed it was stopping development of its lead pipeline drug revusiran. A phase III trial of revusiran in the rare disease ...

It's something about revusiran's target or ATTR amyloidosis, so two of Alnylam's pipeline targets, patisiran and ALN-TTRsc02, that are designed to knockdown the same protein could be affected.

But now Alnylam is to abandon revusiran, its second most advanced candidate after 18 patients in the treatment arm of a phase 2 trial died, a much higher rate than those taking placebo.

John Maraganore, CEO at Alnylam, said: “Patient safety comes first. We have stopped all dosing and are actively monitoring patients across revusiran studies to ensure their safety. We will also ...

As of 5:40 p.m., Alnylam's (Nasdaq ... said it’s stopping development of revusiran, a drug for a debilitating and often fatal disease called hereditary ATTR amyloidosis with cardiomyopathy.

Despite a good track record of drug development, ATTR-CM has been a tough target for Alnylam, and past failures (revusiran and Onpattro) are likely to drive elevated skepticism for HELIOS-B.